Hormonal
Metformin is the most effective pharmacological intervention for preventing type 2 diabetes in prediabetic patients, significantly reducing diabetes incidence and improving glucose tolerance compared to lifestyle interventions alone.
If you have prediabetes, metformin is a highly effective, safe, and well-tolerated medication recommended by the American Diabetes Association to prevent diabetes. Start with a low dose (500 mg) to minimize gastrointestinal side effects like diarrhea, and work up to 1000 mg twice daily. Monitor Vitamin B12 levels if taking it long-term. It is particularly useful if you find sustaining strict lifestyle changes difficult.
The American Diabetes Association states that metformin is the most effective drug for diabetes prevention and recommends its use for prediabetes intervention[2]. ... Compared with the placebo group, 17% lower incidence of diabetes [with metformin].
Why this rating
Supported by multiple clinical trials (Diabetes Prevention Program) and ADA guidelines cited in the review.
Source
Metabolic disorders in prediabetes: From mechanisms to therapeutic management
Wen-Xin Ping et al. · World Journal of Diabetes · 2024
DOI 10.4239/wjd.v15.i3.361
More from this paper
- GLP-1 receptor agonists (GLP-1RAS) significantly reduce body weight and improve glucose tolerance in prediabetic patients, offering a potent alternative to metformin, particularly for those with obesity.Good
- SGLT2 inhibitors reduce blood glucose and body weight in prediabetic patients by increasing urinary glucose excretion, effectively delaying diabetes development.Good
- Vitamin D supplementation (≥ 1000 IU/day) reduces the risk of developing diabetes in individuals with prediabetes by improving insulin sensitivity and beta-cell function.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →